Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy

Diabetes, Obesity and Metabolism

Volumn 13, Issue 7, 2011, Pages 577-583

  Rabbani, N ^a   Thornalley, P J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Clinical trial; Diabetes complications; Diabetic nephropathy

Indexed keywords

ALBUMIN; BENFOTIAMINE; COCARBOXYLASE; GLUCOSE; INSULIN; PLACEBO; THIAMINE; THIOCTIC ACID; TRANSKETOLASE;

DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STREPTOZOCIN DIABETES; URINARY EXCRETION; VITAMIN METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 79956293554     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01384.x     Document Type: Review

References (82)

1. Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care 2010; 33: 1320-1324.
2. Williams ME. Diabetic CKD/ESRD 2010: a progress report? Semin Dial 2010; 23: 129-133.
3. American Diabetes Association. Standards of medical care in diabetes-2009. Diabetes Care 2009; 32: S13-61.
4. Bergmann AK, Sahai I, Falcone JF et al. Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update. J Pediatr 2009; 155: 888-892.
5. Fleming JC, Tartaglini E, Steinkamp MP, Schorderet DF, Cohen N, Neufeld EJ. The gene mutated in thiamine-responsive anaemia with diabetes and deafness (TRMA) encodes a functional thiamine transporter. Nat Genet 1999; 22: 305-308.
6. Labay V, Raz T, Baron D et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999; 22: 300-304.
7. Diaz GA, Banikazemi M, Oishi K, Desnick RJ, Gelb BD. Mutations in a new gene encoding a thiamine transporter cause thiamine-responsive megaloblastic anaemia syndrome. Nat Genet 1999; 22: 309-312.
8. Valerio G, Franzese A, Poggi V, Tenore A. Long-term follow-up of diabetes in two patients with thiamine-responsive megaloblastic anemia syndrome. Diabetes Care 1998; 21: 38-41.
9. Rajgopal A, Edmondnson A, Goldman ID, Zhao RB. SLC19A3 encodes a second thiamine transporter ThTr2. Biochim Biophys Acta Mol Basis Dis 2001; 1537: 175-178.
10. Matherly LH. Molecular and cellular biology of the human reduced folate carrier. Prog Nucleic Acid Res Mol Biol 2001; 67: 131-162.
11. Zhao R, Gao F, Goldman ID. Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 2002; 282: C1512-1517.
12. Zhao RB, Gao F, Wang YH, Diaz GA, Gelb BD, Goldman ID. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2001; 276: 1114-1118.
13. Lindhurst MJ, Fiermonte G, Song S et al. Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. PNAS 2006; 103: 15927-15932.
14. Kang J, Samuels DC. The evidence that the DNC (SLC25A19) is not the mitochondrial deoxyribonucleotide carrier. Mitochondrion 2008; 8: 103-108.
15. Said HM, Balamurugan K, Subramanian VS, Marchant JS. Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine. Am J Physiol Gastrointest Liver Physiol 2004; 286: G491-498.
16. Dutta B, Huang W, Molero M et al. Cloning of the human thiamine transporter, a member of the folate transporter family. J Biol Chem 1999; 274: 31925-31929.
17. Reidling JC, Subramanian VS, Dudeja PK, Said HM. Expression and promoter analysis of SLC19A2 in the human intestine. Biochim Biophys Acta 2002; 1561: 180-187.
18. Eudy JD, Spiegelstein O, Barber RC, Wlodarczyk BJ, Talbot J, Finnell RH. Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. Mol Genet Metab 2000; 71: 581-590.
19. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE. The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci USA 2001; 98: 2284-2288.
20. Gastaldi G, Coya E, Verri A, Laforenza U, Faelli A, Rindi G. Transport of thiamin in rat renal brush border membrane vesicles. Kidney Int 2002; 57: 2043-2054.
21. Trippett TM, Garcia S, Manova K et al. Localization of a human reduced folate carrier protein in the mitochondrial as well as the cell membrane of leukemia cells. Cancer Res 2001; 61: 1941-1947.
22. Zhao R, Gao F, Wang Y, Diaz GA, Gelb BD, Goldman ID. Impact of the reduced folate carrier on the accumulation of active thiamin metabolites in murine leukemia cells. J Biol Chem 2001; 276: 1114-1118.
23. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ. High dose thiamine therapy counters dyslipidaemia in streptozotocin-induced diabetic rats. Diabetologia 2004; 47: 2235-2246.
24. Chin E, Zhou J, Bondy C. Anatomical and developmental patterns of facilitative glucose transporter gene-expression in the rat kidney. J Clin Invest 1993; 91: 1810-1815.
25. Tallaksen CME, Bohmer T, Karlsen J, Bell H. Determination of thiamin and its phosphate esters in human blood, plasma, and urine. Vitam Coenzymes 1997; 279(Pt I): 67-74.
26. Morshed KM, Ross DM, McMartin KE. Folate transport proteins mediate the bidirectional transport of 5-methyltetrahydrofolate in cultured human proximal tubule cells. J Nutr 1997; 127: 1137-1147.
27. Rindi G, Laforenza U. Thiamine intestinal transport and related issues: recent aspects. PSEBM 2000; 224: 246-255.
28. Laforenza U, Patrini C, Alvisi C, Faelli A, Licandro A, Rindi G. Thiamine uptake in human intestinal biopsy specimens, including observations from a patient with acute thiamine deficiency. Am J Clin Nutr 1997; 66: 320-326.
29. European Food Safety Authority. Scientific opinion of the panel on food additives and nutrient sources added to food (ANS) on a request from the Commission on benfotiamine, thiamine monophosphate chloride and thiamine pyrophosphate chloride, as sources of vitamin B1. EFSA J 2008; 864: 1-31.
30. Finglas PM. Thiamin. Int J Vitam Nutr Res 1993; 63: 270-274.
31. Tasevska N, Runswick SA, McTaggart A, Bingham SA. Twenty-four-hour urinary thiamine as a biomarker for the assessment of thiamine intake. Eur J Clin Nutr 2007; 62: 1139-1147.
32. Patrini C, Laforenza U, Gastaldi G, Verri A, Ferrari G, Rindi G. Effects of insulin on thiamine intestinal transport in rat everted jejunal sacs. J Physiol (Lond) 1996; 493: 100S-101S.
33. Thornalley PJ, Babaei-Jadidi R, Al Ali H et al. High prevalence of low plasma thiamine concentration in diabetes linked to marker of vascular disease. Diabetologia 2007; 50: 2164-2170.
34. Rabbani N, Shahzad Alam S, Riaz S et al. High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomised, double-blind, placebo-controlled study. Diabetologia 2009; 52: 208-212.
35. AntonySunil A, Babaei-Jadidi R, Rabbani N et al. Increased thiamine transporter contents of red blood cells and peripheral blood mononuclear leukocytes in type 1 and type 2 diabetic patients. Diabetes 2007; 56: A609.
36. Larkin JR, Thornalley PJ. High glucose causes a decrease in expression of thiamine transporters in human proximal tubule epithelial cells in vitro. Diabetologia 2008; 51: 219.
37. Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ. Prevention of incipient diabetic nephropathy by high dose thiamine and Benfotiamine. Diabetes 2003; 52: 2110-2120.
38. Patrini C, Griziotti A, Ricciardi L. Obese individuals as thiamin storers. Int J Obes 2004; 28: 920-924.
39. Weber W, Kewitz H. Determination of thiamine in human plasma and its pharmacokinetics. Eur J Clin Pharmacol 1985; 28: 213-219.
40. Ariaey-Nejad MR, Balaghi M, Baker EM, Sauberlich HE. Thiamin metabolism in man. Am J Clin Nutr 1970; 23: 764-778.
41. Weber W, Nitz M, Looby M. Nonlinear kinetics of the thiamine cation in humans-saturation of nonrenal clearance and tubular reabsorption. J Pharmacokinet Biopharm 1990; 18: 501-523.
42. Bellazzi R, Guglielmann R, Ironi L, Patrini C A. Hybrid input-output approach to model metabolic systems: an application to intracellular thiamine kinetics. J Biomed Inform 2001; 34: 221-248.
43. Perkins BA, Ficociello LH, Ostrander BE et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18: 1353-1361.
44. AntonySunil A, Perkins B, Krolewski A, Rabbani N, Thornalley PJ. Thiamine status and risk of early renal function decline in type 1 diabetic patients. Diabetologia 2008; 51: S98.
45. Xue M, Qian Q, Adaikalakoteswari A, Rabbani N, Babaei-Jadidi R, Thornalley PJ. Activation of NF-E2-related factor-2 reverses biochemical dysfunction of endothelial cells induced by hyperglycemia linked to vascular disease. Diabetes 2008; 57: 2809-2817.
46. Cheng JZ, Yang YS, Singh SP et al. Two distinct 4-hydroxynonenal metabolizing glutathione S-transferase isozymes are differentially expressed in human tissues. Biochem Biophys Res Commun 2001; 282: 1268-1274.
47. Thornalley PJ, Qian Q, Rabbani N. Prevention of dicarbonyl stress induced by hyperglycaemia in microvascular endoethelial cells by sulforaphane. Diabetologia 2008; 51: 1301.
48. Hammes H-P, Du X, Edelstein D et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
49. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley P. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010; 53: 1506-1516.
50. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
51. Brady JA, Rock CL, Horneffer MR. Thiamin status, diuretic medications, and the management of congestive heart failure. J Am Diet Assoc 1995; 95: 541-544.
52. Soh Y, Song BJ, Jeng JJ, Kallarakal AT. Critical role of Arg(433) in rat transketolase activity as probed by site-directed mutagenesis. Biochem J 1998; 333: 367-372.
53. Lapsys NM, Layfield R, Baker E et al. Chromosomal location of the human transketolase gene. Cytogenet Cell Genet 1992; 61: 274-275.
54. Freedman BI, Bowden DW, Rich SS et al. Genome-wide linkage scans for renal function and albuminuria in type 2 diabetes mellitus: the Diabetes Heart Study. Diabet Med 2008; 25: 268-276.
55. Pacal L, Tomandl J, Tanhauserova V et al. Thiamine levels and transketolase genetic variants as modifiers of progression of diabetic nephropathy. Diabetologia 2009; 52: 1079.
56. Balakumar P, Chakkarwar VA, Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell. Biochem 2009; 320: 149-162.
57. Rabbani N, Alam S, Riaz S et al. Thiamine in diabetic nephropathy: a novel treatment modality? Reply to Alkhalaf A, Kleefstra N, Groenier KH et al. [letter]. Diabetologia 2009; 52: 1214-1216.
58. Araki Si, Haneda M, Koya D et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007; 56: 1727-1730.
59. Sihag B, Meena B, Agrawal R, Meel J, Sirohi P, Bishnoi P. High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled study. Diabetes Obes Metab 2010; 12: 87-88.
60. Alkhalaf A, Klooster A, van Oeveren W et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010; 33: 1598-1601.
61. Satchell S, Tooke J. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 714-725.
62. Kim D, Nam H. The effect of benfotiamine on endothelial function in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 1202.
63. Du X, Edelstein D, Brownlee M. Oral benfotiamine plus α-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia 2008; 51: 1930-1932.
64. Ascher E, Gade PV, Hingorani A et al. Thiamine reverses hyperglycemia-induced dysfunction in cultured endothelial cells. Surgery 2001; 130: 851-858.
65. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281: 9307-9313.
66. LaSelva M, Beltramo E, Pagnozzi F et al. Thiamine corrects delayed replication and decreases production of lactate and advanced glycation endproducts in bovine retinal and human umbilical vein endothelial cells cultured under high glucose conditions. Diabetologia 1997; 39: 1263-1268.
67. Beltramo E, Berrone E, Buttiglieri S, Porta M. Thiamine and benfotiamine prevent increased apoptosis in endothelial cells and pericytes cultured in high glucose. Diabetes Metab Res Rev 2004; 20: 330-336.
68. Arora S, Lidor A, Abularrage CJ et al. Thiamine (vitamin B-1) improves endothelium-dependent vasodilatation in the presence of hyperglycemia. Ann Vasc Surg 2006; 20: 653-658.
69. Potter DR, Jiang J, Damiano ER. The recovery time course of the endothelial cell glycocalyx in vivo and its implications in vitro. Circ Res 2009; 104: 1318-1325.
70. van Balkom BWM, Savelkoul PJM, Markovich D et al. The role of putative phosphorylation sites in the targeting and shuttling of the aquaporin-2 water channel. J Biol Chem 2002; 277: 41473-41479.
71. Zelenina M, Zelenin S, Bondar AA, Brismar H, Aperia A. Water permeability of aquaporin-4 is decreased by protein kinase C and dopamine. Am J Physiol Renal Physiol 2002; 283: F309-318.
72. Shindo H, Okamoto K, Totsu J. Transport of organic compounds through biological membranes. I. Accumulative uptake of S-benzoylthiamine by human erythrocytes. Chem Pharm Bull 1967; 15: 295-302.
73. Volvert ML, Seyen S, Piette M et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol 2008; 8: 10.
74. Ziems M, Netzel M, Bitsch I. Biokinetic of S-benzoylthiamine-O-monophosphate in human. Vitam Addit Hum Anim Nutr 1997;194-199.
75. Thornalley PJ, Babaei-Jadidi R. Prevention of microvascular complications of diabetes by high dose S-benzoylthiamine monophosphate (benfotiamine): mechanism of thiamine delivery into cells. Diabetologia 2005; 48: A377.
76. Wakabayashi Y. Purification and properties of porcine thiamine pyrophosphokinase. Vitamins 1978; 52: 223-236.
77. Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Res 2005; 1: 287-298.
78. Heinze T, Weber W. Determination of thiamine (vitamin B1) in maternal blood during normal pregnancies and pregnancies with intrauterine growth retardation. Z Ernahrungswiss 1990; 29: 39-46.
79. Kohda Y, Shirakawa H, Yamane K et al. Prevention of incipient diabetic cardiomyopathy by high-dose thiamine. J Toxicol Sci 2008; 33: 459-472.
80. Ceylan-Isik AF, Wu S, Li Q, Li SY, Ren J. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol 2006; 100: 150-156.
81. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Prevention of decline in glycaemic control in streptozotocin-induced diabetic rats by thiamine but not by benfotiamine. Diabetic Med 2010; 27(Suppl. 1): 74.
82. Bakker SJL, Hoogeveen EK, Nijpels G et al. The association of dietary fibres with glucose is partly explained by concomitant intake of thiamine: the Hoorn study. Diabetologia 1998; 41: 1168-1175 [abstract].